Valeant Pharmaceuticals International, Inc.
) recently announced that it has acquired rights to Targretin
(bexarotene) capsules and Targretin (bexarotene) gel 1% in the US
from Eisai, Inc., the pharmaceutical arm of Eisai Co., Ltd. in
Valeant Pharmaceuticals paid $65 million upfront for these
rights. The company will make further contingent payments based
on certain milestones as and when achieved.
Under the terms of the agreement, Eisai transferred the New
Drug Application (NDA) for Targretin to Valeant.
Henceforth, Valeant will be responsible for all regulatory
obligations related to Targretin in the US.
However, Eisai retained its rights to Targretin outside the US
and will continue to market the product internationally.
Targretin capsules are primarily used to treat skin problems
caused by cutaneous T-cell lymphoma (CTCL) when at least one
systemic therapy has not worked.
Targretin gel is used for the topical treatment of skin
lesions in patients with CTCL (stage IA and IB) when other
therapies did not work or were not tolerated.
Valeant Pharmaceuticals, a Canada-based specialty
pharmaceutical company, develops, manufactures and markets
multiple pharmaceutical products primarily in the fields of
dermatology, neurology and branded generics.
In order to bolster its product portfolio, Valeant Pharma
acquired all of the outstanding common stock of Medicis
Pharmaceutical Corporation for approximately $2.6 billion in Dec
The erstwhile Medicis Pharma focused on the development and
marketing of products for the treatment of dermatological and
aesthetic conditions in the US. The acquisition has further
strengthened Valeant Pharma's product portfolio in the
We note that acquisition activity has been quite strong in
recent times in the dermatological segment. Apart from Valeant
Pharma's acquisition of Medicis Pharma, the acquisition of
specialty dermatology generics company, Fougera Pharma by
) in Jul 2012, was also in the news.
) acquired privately-held SkinMedica, Inc. in Dec 2012 with a
focus on the latter's topical aesthetics skin care business.
Valeant Pharmaceuticals currently carries a Zacks Rank #3
(Hold). Right now,
Salix Pharmaceuticals Ltd.
) is better positioned with a Zacks Rank #2 (Buy).
ALLERGAN INC (AGN): Free Stock Analysis
NOVARTIS AG-ADR (NVS): Free Stock Analysis
SALIX PHARM-LTD (SLXP): Free Stock Analysis
VALEANT PHARMA (VRX): Free Stock Analysis
To read this article on Zacks.com click here.